EQUITY ALERT: Rosen Law Firm Announces Filing of Securities

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
75
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Aratana Therapeutics, Inc. – PETX

NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Aratana Therapeutics, Inc. securities (NASDAQ: PETX ) from March 16, 2015 through February 3, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aratana investors under the federal securities laws.

To join the Aratana class action, go to http://rosenlegal.com/cases-1049.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aratana did not have manufacturing contracts in place sufficient to support manufacturing of ENTYCE at a commercial scale; (2) consequently, ENTYCE was not likely to be commercially available until late 2017; (3) accordingly, Aratana had misled investors with respect to the likely timeline for a commercial launch of ENTYCE; and (4) as a result, Aratana’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1049.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com .

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm .

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 lrosen@rosenlegal.com pkim@rosenlegal.com kchan@rosenlegal.com www.rosenlegal.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Viatris Declares Quarterly Dividend Amid Acquisition Buzz

Updated Category News Views 65

A Dividend Declaration with a Side of Mergers Viatris, the healthcare giant operating on a global scale, has been making some noise recently. On the surface, it's another quarterly dividend—$0.12 per share, set to hit the pockets of shareholders on December 16. But there's a lot more cooking under the hood of this announcement that ticks just about every box for a...

Continue Reading
Lululemon Faces Lawsuit Over Alleged Fraudulent Reporting

Updated Category News Views 110

What's Stirring the Pot for Lululemon? Talk about a rollercoaster. Over here, Lululemon (NASDAQ:LULU) is navigating turbulent waters, facing a class action lawsuit for alleged securities fraud. Investors who bought into the brand between March 18, 2026, and September 3, 2026, are now watching their investments drop, following what's claimed as misleading trumpet calls...

Continue Reading
Greenberg Traurig's Stars Shine in Delaware's Legal Scene

Updated Category News Views 56

Five Lawyers, One Prestigious List Eating lunch today, I nearly dropped my sandwich when I read that five top-notch attorneys from Greenberg Traurig have snagged spots on Delaware Today's 2026 Top Lawyers List. This isn't your everyday pat on the back; it's Delaware, the heavyweight champ of corporate law, after all. The Legal Eagles of Greenberg Traurig Kicking off this...

Continue Reading
Samsung Ups Stake in TCL CSOT: A Game-Changer?

Updated Category News Views 137

Samsung Electronics' Strategic Play Sometimes it takes a gutsy move to shake up the industry, and Samsung Electronics just went for it. Snagging a 10.16% stake in TCL CSOT isn't just some run-of-the-mill acquisition. It's a calculated chess piece placement in the cutthroat display tech arena. Unpacking the Stake Game This latest move shifts Samsung Display's stake to...

Continue Reading
Black Friday Doubt Grows: Just 54% Trust Real Deals

Updated Category News Views 93

Do Shoppers Believe in Black Friday Anymore? You'd think by now, retailers would have cracked the code on building trust with their customers. But guess what? A fresh survey from Boston Consulting Group reveals only 54% of consumers buy the whole Black Friday discount story. That's barely more than flipping a coin. Promotion Fatigue: The Trust Buster Funny thing,...

Continue Reading
LULU Under Fire: Class Action Opportunities Await

Updated Category News Views 138

Lululemon Faces a Legal Storm If you're holding shares in Lululemon (NASDAQ: LULU), you might want to sit up and pay attention. Schall, Brown & Schwartz LLP, a national shareholder rights litigation firm, is gathering folks for a securities fraud class action lawsuit against Lululemon. They're pointing fingers at the company for cooking the books – or at least not being...

Continue Reading
Askey & Icom Team Up: Trading Airwaves for Partnerships

Updated Category News Views 20

Old-School Radios Meet Cutting-Edge 5G When I hear about a company linking their old-school tech with shiny new 5G jazz, skepticism kicks in fast. But then comes this announcement: Askey and Icom America are joining forces to bring 5G networks with integrated two-way radio systems to various sectors—like a classic combo meal with a tech twist. The key audience? Utility...

Continue Reading
Sectra Powers Radiology at Mount Sinai with AI Integration

Updated Category News Views 97

AI and Radiology: A Match Made for Mount Sinai Today, we're diving into a technological leap that promises to shake up the healthcare sector—Sectra's integration of artificial intelligence with radiology at Mount Sinai Health System. The deal pairs Sectra's prowess in medical imaging IT and cybersecurity with the healthcare giant in New York, aiming to redefine how...

Continue Reading
DarioHealth Taps Palumbo to Drive Healthcare Evolution

Updated Category News Views 32

Strategic Leadership for an Evolving Market Prepare your portfolios, folks. DarioHealth Corp. (NASDAQ:DRIO) is gearing up to ride a seismic shift in healthcare. John R. Palumbo's appointment as Chairman of the Board marks a bold move as Dario looks to dominate the new convergence of consumer-directed and payer-funded healthcare. This isn't just a change of guard; it's a...

Continue Reading
Atlas-SSI Expands Grip in Water Control Space

Updated Category News Views 191

Atlas-SSI Makes Waves with Linita Acquisition Here's the kind of news that makes an old market hound sit up and take notice. Atlas-SSI, the big cheese in North America for water management solutions, has gone and snagged Linita Design & Manufacturing. Why's this worth talking about? Linita isn't just any player—they've been crafting custom-engineered hydro-mechanical...

Continue Reading

Top 5 Most Recently Viewed Articles

Medicenna Reveals Promising MDNA11 Results at SITC Meeting

Updated Category News Views 197

Medicenna's Groundbreaking MDNA11 Updates Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, recently made headlines at a prominent annual meeting dedicated to cancer research. Their innovative approach using MDNA11, a long-acting interleukin-2 super-agonist, is showing significant promise, particularly in the context of advanced solid tumors that have...

Continue Reading
Melco Resorts Restructures Operations for Future Growth

Updated Category News Views 267

Melco Resorts Announces Strategic Changes to Casino Operations Recent developments from Melco Resorts & Entertainment Limited (Nasdaq: MLCO) signal a significant shift in the company's operational strategy. The company, known for its luxurious integrated resort facilities across Asia and Europe, has made the difficult decision to cease operations at the Grand Dragon...

Continue Reading
Verizon Highlights Surge in Cyber Threats in Latest Report

Updated Category News Views 489

Insights from Verizon's 2025 Data Breach Investigations Report In a pivotal revelation, Verizon Business has issued its latest Data Breach Investigations Report, shedding light on an unsettling surge in system intrusions affecting organizations across the Asia-Pacific region. The report emphasizes that a staggering 80% of reported data breaches can be traced back to these...

Continue Reading
BrookBridge Wealth Transitions to LPL Private Wealth Management

Updated Category News Views 109

BrookBridge Private Wealth Joins LPL Financial BrookBridge Private Wealth has officially joined LPL Financial, a move designed to deepen client service and widen what the firm can offer. By aligning with LPL, the team can focus on high-net-worth clients while keeping the personalized, one-to-one approach that defines their work. The transition gives them room to tailor...

Continue Reading
Breckenridge Expands Product Line with Everolimus Approval

Updated Category News Views 225

Breckenridge Announces FDA Approval for Everolimus Tablets In an impressive stride towards enhancing healthcare accessibility, Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International, recently revealed the final FDA approval for Everolimus Tablets for Oral Suspension (TFOS). This generic medication, available in 2mg, 3mg, and 5mg doses, serves as a...

Continue Reading